Blog
Drug Target Encyclopedia Series (42) —PCSK9
Release Time：
2026-08-06 16:17
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a key regulator of cholesterol metabolism and plays an important role in controlling low-density lipoprotein cholesterol (LDL-C) levels.
By binding to the LDL receptor (LDLR) on hepatocytes and promoting LDLR degradation, PCSK9 reduces hepatic clearance of circulating LDL-C, leading to elevated plasma cholesterol levels.
Dysregulated PCSK9 activity is strongly associated with hypercholesterolemia, atherosclerosis, and cardiovascular disease, making it one of the most validated targets in lipid-lowering drug development.
🧬 PCSK9 is highly relevant in:
• Familial hypercholesterolemia
• Hyperlipidemia
• Atherosclerotic cardiovascular disease (ASCVD)
• Coronary artery disease
• Cardiovascular risk management
• Lipid metabolism research
🎯 Targeting PCSK9 in drug development:
🧪 Monoclonal antibodies – Block PCSK9 interaction with LDLR, preventing LDLR degradation and increasing LDL-C clearance.
🧪 RNA-based therapeutics – Utilize siRNA or other RNA modalities to reduce PCSK9 expression and achieve sustained cholesterol lowering.
🧪 Gene editing approaches – Explore permanent PCSK9 pathway modulation for long-term therapeutic effects.
🧪 Small molecule inhibitors – Investigate alternative approaches to interfere with PCSK9 activity and LDLR regulation.
🧪 Biomarker and functional studies – Evaluate PCSK9 expression, LDLR recycling, and lipid metabolism pathways.
💥 Challenges include:
• Achieving long-term and controllable PCSK9 inhibition
• Optimizing delivery strategies for nucleic acid therapeutics
• Understanding patient-specific responses
• Balancing efficacy, safety, and treatment durability
• Developing next-generation approaches beyond antibody therapies
🔬 PCSK9 remains a landmark target in cardiovascular drug discovery. The success of PCSK9 inhibitors has validated the potential of target-based lipid regulation and continues to inspire new therapeutic strategies, including RNA medicines and gene-based approaches.
As new technologies emerge, PCSK9 continues to serve as an important model for developing innovative approaches in metabolic and cardiovascular medicine.
🔍 Is PCSK9 part of your immuno-oncology or immune modulation drug discovery pipeline?
Fill out the form below, or visit the link: to browse the complete list of available in-stock products.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898